New Systemic Therapies in Hepatocellular Carcinoma

Program Overview

For over a decade, sorafenib was the only systemic agent available for the treatment of advanced hepatocellular carcinoma (HCC). However, the past 2.5 years has added 6 additional agents. In this Clinical ForumSM, our multidisciplinary expert roundtable convenes to discuss their collaborative care strategies for first and subsequent line management of advanced HCC using case-based scenarios.

Credit Expired

Target Audience

This activity is designed to meet the educational needs of oncology providers, including physicians, nurse practitioners, and physician assistants who manage patients with hepatocellular carcinoma (HCC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Appropriately utilize multi-targeted tyrosine kinase inhibitors for the management of advanced hepatocellular carcinoma (HCC) based on clinical evidence for their use
  • Incorporate immune checkpoint inhibitors in the management of advanced HCC based on their efficacy and safety data
  • Select appropriate therapy for patients with advanced HCC across multiple lines of therapy

Activity Faculty


Ghassan K. Abou-Alfa, MD, MBA (Chair)

Memorial Sloan Kettering Cancer Center
New York, NY


Anne M. Covey, MD

Memorial Hospital for Cancer and Allied Diseases
New York, NY


Amit Singal, MD, MS

David Bruton Jr. Professor, Clinical Cancer Research
Associate Professor, Medicine
Medical Director, Liver Tumor Program
Clinical Chief, Hepatology
University of Texas Southwestern
Dallas, TX


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources